Comparative Pharmacology
Head-to-head clinical analysis: CORTALONE versus FLUOCINONIDE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTALONE versus FLUOCINONIDE ACETONIDE.
CORTALONE vs FLUOCINONIDE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Fluocinonide acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
Apply a thin film to affected area 1 to 3 times daily, depending on severity. Maximum: 2 weeks continuous use. Not for use on face, groin, or axillae. Dispense 15-60 g per application.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 48-72 hours; prolonged in hepatic impairment due to reduced clearance; duration of action at skin sites persists up to 4-6 hours post-application.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% unchanged drug in urine; biliary/fecal excretion accounts for ~60% of metabolites.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid